Vardenafil Improved Erectile Function in a “Real‐Life” Broad Population Study of Men with Moderate to Severe Erectile Dysfunction in Australia and New Zealand

ABSTRACT Introduction Phosphodiesterase type 5 inhibitor drugs produce vasodilatation by inhibiting the breakdown of cyclic guanosine monophosphate and have proven efficacy in treating erectile dysfunction (ED). Aim To evaluate the efficacy, safety, and tolerability of vardenafil in men with moderate to severe ED of broad etiology. Main Outcome Measures The erectile function (EF) domain score, the response to Questions 13 and 14 of the International Index of Erectile Function (IIEF) questionnaire, and the proportion of “yes” responses to questions 2 and 3 of the Sexual Encounter Profile (SEP), a Global Assessment (GAQ), and Global Satisfaction Questions (GSQ) were compared at baseline and at 12 weeks of treatment with as‐needed vardenafil. Methods A total of 326 subjects with a mean age of 57.6 years and moderate to severe erectile dysfunction of various etiologies received vardenafil (5–20 mg) for 12 weeks in a prospective multicenter, open‐label flexible‐dose study. Results Compared with baseline, vardenafil was superior in all efficacy outcomes. A significant mean improvement of 13.4 ( P P Conclusions Vardenafil was effective and well tolerated in men with moderate to severe erectile dysfunction. Treatment with vardenafil was associated with a significantly higher IIEF erectile function domain score and completion of successful intercourse rate compared with baseline. McMahon C, Lording D, Stuckey B, Tan V, Gillman M, White W, Di Natale S, and Bramwell P. Vardenafil improved erectile function in a “real‐life” broad population study of men with moderate to severe erectile dysfunction in Australia and New Zealand. J Sex Med 2006;3:892–900.